Program News
News and stories about the UNC Lineberger Cellular Immunotherapy Program
-
Parents, supporters create new fund for CAR-T therapy
Inspired by the potential of immunotherapy in solid tumor cancers, Tom and Nancy Chewning established a fund to support Jonathan Serody, MD, and accelerate his work with CAR-T immunotherapy.
-
Engineered safety switch curbs severe side effects of CAR-T immunotherapy
As part of a study led by Matthew Foster, MD, the advance was seen in a patient enrolled in a clinical trial using CAR-T to treat refractory acute B-cell leukemia.
-
European Medicines Agency awards priority designation for Hodgkin lymphoma CAR-T therapy
The European Medicines Agency granted priority medicines designation to Tessa Therapeutics’ CD30 targeted CAR-T therapy for patients with relapsed or refractory Hodgkin lymphoma.
-
Excellent research results for CAR-T therapy against Hodgkin lymphoma
CAR-T immunotherapy has been used to treat Hodgkin lymphoma with remarkable success for the first time, according to the results of an early phase clinical trial.
-
CAR-T therapy gives patient options after cancer returns
When traditional cancer treatment options failed, Sabrina Shelton’s care team referred her to UNC for a CAR-T therapy clinical trial.
-
UNC Lineberger discovery would allow researchers to fine-tune activity of cancer-hunting immune cells
A discovery by University of North Carolina Lineberger Comprehensive Cancer Center researchers could allow scientists to fine-tune genetically engineered immune cells to heighten their killing power against tumors or to decrease their activity level in the case of severe side effects. In a study published in Cancer Cell, researchers led by UNC Lineberger’s Gianpietro Dotti, … Continued
-
UNC Lineberger designs, develops and delivers CAR-T therapy to attack cancers
Jonathan Serody, MD, explains in a two-minute video the action behind chimeric antigen T-cell, or CAR-T, immunotherapy and how UNC Lineberger is designing, developing and delivering CAR-T therapies to treat cancers that fail to respond to standard treatments.
-
Stand Up To Cancer names UNC Lineberger researchers to ‘Dream Team’
The multi-institutional team, which is co-led by UNC Lineberger’s Gianpietro Dotti, MD, and includes six UNC Lineberger researchers, will focus on developing chimeric antigen receptor T-cell (CAR-T) therapies to recognize and attack T-cell lymphoma, a group of rare cancers of the blood and immune system.